Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Natco Pharma Ltd.

www.natcopharma.co.in

Latest From Natco Pharma Ltd.

Indian Court Rebuffs Bayer In Bolar Exemption Case

The Delhi High Court has rejected Bayer’s contention around certain key aspects of India’s Bolar provision – the experimental use or early working exception – and held that “sale” both within the country and abroad is permitted under these norms, subject to certain conditions.

Commercial Companies

Will Shareholders Support The Bristol/Celgene Merger? – An Informa Pharma Intelligence Podcast

Expectations that the $74bn deal will go through are now reinforced by proxy advisor recommendations that shareholders vote in favor of the transaction. Podcast discussion also includes Karyopharm’s selinexor and J&J’s Spravato.

Deals Business Strategies

Celgene/Bristol's Revlimid Patent Risk Incrementally Lower After PTAB Denies Alvogen IPR

Bristol-Myers Squibb pitches Celgene's pipeline as its most valuable asset, but investors remain fixated on the coming Revlimid patent cliff. A recent PTAB decision to deny an inter partes review incrementally decreased that risk.

Intellectual Property Business Strategies

Natco-Alvogen Claim First Filer ANDA Status For Imbruvica Tablet Form

Natco and Alvogen Pine Brook have entered the arena for a potential generic version of AbbVie/Johnson & Johnson’s Imbruvica through a US ANDA filing for the tablet version of the BTK-inhibitor.
Policy & Regulation Generic Drugs
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Natco Pharma Ltd.
  • Senior Management
  • P. Bhaskara Narayana, CFO
    VC Nannapaneni, Chmn. & Managing Dir.
    Aks Bhujanga Rao, Pres., R&D
  • Contact Info
  • Natco Pharma Ltd.
    Phone: (91) 40 2354 7532
    Natco House, Road No. 2
    Banjara Hills
    Hyderabad, 500033
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register